Andrew Robinson
Chief Executive Officer
Yeah. So great question, Alex. And you're right with how you framed it. You know, there's a lot about sort of the specifics of our business that probably makes unpacking it a little bit more difficult. But, you know, overall, I think we're still in the view that loss cost trend in our portfolio in total is somewhere in the five to six range. By and large, we've tried to limit the amount of exposure we have in what we see as being sort of the high inflation exposed bodily injury categories in casualty and liability. I think one of the things that we make that we do is we're keeping our limits short. Much of what we do in access is written over our own primary. And so, you know, from a casualty perspective, we're trying to keep it in check as much as we can. You know, on the property side, you know, there's probably a few different pieces to it. I think, you know, from an inflation related to tariffs, you know, we probably have some in APD and certain on the global property side, you know, reconstruction costs are going to go up. I think on the flip side, you know, much of what we have inside of our E and S portfolio is a cash value. And so I think it's less inflation exposed. And as I've mentioned in the past, as materials go up, we benefit from that on surety because effectively, you're getting a bond that's increasing in size without sort of a proportionate, you know, loss cost increase. And so we have some countermeasures that are beneficial in our book. I think the other thing I'd say to you, Alex, is that, you know, a little bit surprises, because we've listened to the questions that have come in prior calls. And while, you know, for us, we're certainly not ignoring the tariffs question. It's clearly on our thinking. We just think that there's so many other things that are going on in the economy to pay attention to that our leaders have started to prepare themselves and are monitoring, whether it be cost shifting in health care, going on. I think, you know, certainly, might impact the cost of drugs and particularly from coming from other countries. I will say that the, you know, the reduction in federal funds that are flowing downstream to states into munis is probably going to lead to a reduction in capital projects and some cost shifting going on. You know, watching sort of the credit environment, you know, we're watching obviously safety, you know, on job sites and so forth because you're going to have probably a reduction in oversight at OSHA. And if we have a softer economy, you know, the sort of the maintenance and attention to safety might come under pressure. So, you know, we're looking at all these things, and you layer on top of it potential, you know, economy that as it gets a little bit tougher, you start to see instances of moral hazard emerging. And so when we think about the environment, you know, we're thinking about all those things. And I have to sort of hand it to the leaders of our organization. They've done an excellent job of sort of outlining, you know, which of those things are potentially impactful to each of their businesses and how it is that we're preparing ourselves from a countermeasures perspective. And so I would just I'd widen the conversation and say, that's the dialogue, and I think we're probably about as well prepared as anybody can be. Given the uncertainty that we're seeing right now.